Claire Higham

Dr. Claire Higham


Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in The Lancet
Verified
Journal Article
Closed access
CHClaire Higham
Claire Higham
GJGudmundur Johannsson
Gudmundur Johannsson
SSStephen M Shalet
Stephen M Shalet

1 May 2001 in Journal of Molecular Biology
Verified
Journal Article
Closed access
EJEmma T.A.S Jaikaran
Emma T.A.S Jaikaran
CHClaire Higham
Claire Higham
LSLouise Serpell
Louise Serpell
JZJesús Zurdo
Jesús Zurdo
MGMichael Gross
Michael Gross
PFPaul E Fraser
Paul E Fraser

1 February 2016 in European Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
DAD B Allen
D B Allen
PBP Backeljauw
P Backeljauw
MBM Bidlingmaier
M Bidlingmaier
BBB M K Biller
B M K Biller
MBM Boguszewski
M Boguszewski
MTM Thorner
M Thorner
Recombinant human GH (rhGH) has been in use for 30 years, and over that time its safety and efficacy in children and adults has been subject to considerable scrutiny. In 2001, a statement from the GH Research Society (GRS) concluded that ‘for approved indications, GH is safe’; however, the statement highlighted a number of areas for on-going surveillance of long-term safety, including cancer risk, impact on glucose homeostasis, and use of high dose pharmacological rhGH treatment. Over the intervening years, there have been a number of publications addressing the safety of rhGH with regard to mortality, cancer and cardiovascular risk, and the need for long-term surveillance of the increasing number of adults who were treated with rhGH in childhood. Against this backdrop of interest in safety, the European Society of Paediatric Endocrinology (ESPE), the GRS, and the Pediatric Endocrine Society (PES) convened a meeting to reappraise the safety of rhGH. The ouput of the meeting is a concise position statement.

1 March 2015 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
JDJudit Dénes
Judit Dénes
FSFrancesca Swords
Francesca Swords
EREleanor Rattenberry
Eleanor Rattenberry
KSKaren Stals
Karen Stals
MOMartina Owens
Martina Owens
MKMárta Korbonits
Márta Korbonits
Context: Pituitary adenomas and pheochromocytomas/paragangliomas (pheo/PGL) can occur in the same patient or in the same family. Coexistence of the two diseases could be due to either a common pathogenic mechanism or a coincidence. Objective: The objective of the investigation was to study the possible coexistence of pituitary adenoma and pheo/PGL. Design: Thirty-nine cases of sporadic or familial pheo/PGL and pituitary adenomas were investigated. Known pheo/PGL genes (SDHA-D, SDHAF2, RET, VHL, TMEM127, MAX, FH) and pituitary adenoma genes (MEN1, AIP, CDKN1B) were sequenced using next generation or Sanger sequencing. Loss of heterozygosity study and pathological studies were performed on the available tumor samples. Setting: The study was conducted at university hospitals. Patients: Thirty-nine patients with sporadic of familial pituitary adenoma and pheo/PGL participated in the study. Outcome: Outcomes included genetic screening and clinical characteristics. Results: Eleven germline mutations (five SDHB, one SDHC, one SDHD, two VHL, and two MEN1) and four variants of unknown significance (two SDHA, one SDHB, and one SDHAF2) were identified in the studied genes in our patient cohort. Tumor tissue analysis identified LOH at the SDHB locus in three pituitary adenomas and loss of heterozygosity at the MEN1 locus in two pheochromocytomas. All the pituitary adenomas of patients affected by SDHX alterations have a unique histological feature not previously described in this context. Conclusions: Mutations in the genes known to cause pheo/PGL can rarely be associated with pituitary adenomas, whereas mutation in a gene predisposing to pituitary adenomas (MEN1) can be associated with pheo/PGL. Our findings suggest that genetic testing should be considered in all patients or families with the constellation of pheo/PGL and a pituitary adenoma.

23 November 2018 in Endocrine Reviews
Verified
Journal Article
Closed access
PDF file
JGJudith Gebauer
Judith Gebauer
CHClaire Higham
Claire Higham
TLThorsten Langer
Thorsten Langer
CDChristian Denzer
Christian Denzer
GBGeorg Brabant
Georg Brabant
The number of patients surviving five or more years after initial cancer diagnosis has significantly increased over the last decades due to considerable improvements in the treatment of many cancer entities. A negative consequence of this is the emergence of long-term sequelae and endocrine disorders account for a high proportion of these. These late effects can occur decades after cancer treatment and affect up to 50% of childhood cancer survivors. Multiple predisposing factors for endocrine late effects have been identified; including radiation, gender and age at the time of diagnosis. A systematic literature search has been conducted using the PubMed database to offer a detailed overview over the spectrum of late endocrine disorders following oncological treatment. The majority of data are based on late effects of treatment in former childhood cancer patients for whom specific guidelines and recommendations already exist, whereas current knowledge concerning late effects in adult onset cancer survivors is much less clear. Endocrine sequelae of cancer therapy include functional alterations in the hypothalamic/pituitary, thyroid, parathyroid, adrenal and gonadal regulation as well as bone and metabolic complications. Surgery, radio-, chemo- and immunotherapy all contribute. Following irradiation endocrine organs such as the thyroid are also at risk for subsequent malignancies. Although diagnosis and management of functional and neoplastic long-term consequences of cancer therapy are comparable to other causes of endocrine disorders, cancer survivors need individually structured follow-up care in specialized surveillance centers to improve care for this rapidly growing group of patients.

1 July 2018 in Endocrine Connections
Verified
Journal Article
Open access
PDF file
CHClaire Higham
Claire Higham
AOA Olsson-Brown
A Olsson-Brown
PCP Carroll
P Carroll
TCT Cooksley
T Cooksley
JLJ Larkin
J Larkin
PTP J Trainer
P J Trainer
Immunotherapy treatment with checkpoint inhibitors (CPI) (CTLA-4 and PD-1 inhibitors) significantly improves survival in a number of cancers. Treatment can be limited by immune-mediated adverse effects including endocrinopathies such as hypophysitis, adrenalitis, thyroiditis and diabetes mellitus. If endocrinopathies (particularly hypocortisolemia) are not recognized early, they can be fatal. The diagnosis and management of endocrinopathies can be complicated by simultaneous multi-organ immune adverse effects. Here, we present Endocrine Emergency Guidance for the acute management of the endocrine complications of checkpoint inhibitor therapy, the first specialty-specific guidance with Endocrinology, Oncology and Acute Medicine input and endorsed by the Society for Endocrinology Clinical Committee. We present algorithms for management: endocrine assessment and management of patients in the first 24 hours who present life-threateningly unwell (CTCAE grade 3–4) and the appropriate management of mild-moderately unwell patients (CTCAE grade 1–2) presenting with features compatible with an endocrinopathy. Other important considerations in relation to hypohysitis and the maintenance of glucocorticoid therapy are discussed.